Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.

Walsh EM, Shalaby A, O'Loughlin M, Keane N, Webber MJ, Kerin MJ, Keane MM, Glynn SA, Callagy GM.

Breast Cancer Res Treat. 2019 Feb;174(1):1-13. doi: 10.1007/s10549-018-5066-6. Epub 2018 Nov 28.

2.

Intracystic papillary carcinoma of the male breast: a case report and review of the literature.

Hussain A, Sweeney KJ, Salman R, Callagy GM, Sweeney I, McLaughlin R.

Ir J Med Sci. 2012 Sep;181(3):329-31. doi: 10.1007/s11845-009-0372-y. Epub 2009 Jul 9. Review.

PMID:
19588226
3.

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.

Callagy GM, Webber MJ, Pharoah PD, Caldas C.

BMC Cancer. 2008 May 29;8:153. doi: 10.1186/1471-2407-8-153. Review.

4.

Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.

Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C.

Clin Cancer Res. 2006 Apr 15;12(8):2468-75. Erratum in: Clin Cancer Res. 2006 Aug 15;12(16):5002.

5.

A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene.

Huang HE, Chin SF, Ginestier C, Bardou VJ, Adélaïde J, Iyer NG, Garcia MJ, Pole JC, Callagy GM, Hewitt SM, Gullick WJ, Jacquemier J, Caldas C, Chaffanet M, Birnbaum D, Edwards PA.

Cancer Res. 2004 Oct 1;64(19):6840-4.

Supplemental Content

Loading ...
Support Center